Journal
STEM CELLS
Volume 36, Issue 4, Pages 474-481Publisher
WILEY
DOI: 10.1002/stem.2783
Keywords
Differentiation; Gene targeting; Induced pluripotent stem cells; Induced pluripotent stem; Retinal photoreceptors; Retina; Retinal pigmented epithelium
Categories
Funding
- Miguel Servet contract of Instituto de Salud Carlos III [PI14-02209, PI16/00409, CP10/00579]
- AFM Telethon
- Fundacion MaratoTV3 Spain
- project Centre of Reconstructive Neuroscience [CZ.02.1.01/0.0./0.0/15_003/0000419]
- Platform of Biomolecular and Bioinformatics Resources of the Institute of Health Carlos III [PT13/0001/0042]
- GACR [P304/12/G069]
Ask authors/readers for more resources
Hereditary retinal dystrophies, specifically retinitis pigmentosa (RP) are clinically and genetically heterogeneous diseases affecting primarily retinal cells and retinal pigment epithelial cells with blindness as a final outcome. Understanding the pathogenicity behind these diseases has been largely precluded by the unavailability of affected tissue from patients, large genetic heterogeneity and animal models that do not faithfully represent some human diseases. A landmark discovery of human induced pluripotent stem cells (hiPSCs) permitted the derivation of patient-specific cells. These cells have unlimited self-renewing capacity and the ability to differentiate into RP-affected cell types, allowing the studies of disease mechanism, drug discovery, and cell replacement therapies, both as individual cell types and organoid cultures. Together with precise genome editing, the patient specific hiPSC technology offers novel strategies for targeting the pathogenic mutations and design therapies toward retinal dystrophies. This study summarizes current hiPSC-based RP models and highlights key achievements and challenges of these cellular models, as well as questions that still remain unanswered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available